Summary An immunoperoxidase technique has been utilised for the demonstration of follicle stimulating hormone (FSH), luteinising hormone (LH) and prolactin (PRL) binding sites in normal human ovaries and in a wide range of benign and malignant epithelial tumours of the ovary. The incidence of FSH, LH and PRL binding was, respectively, 32%, 41% and 39% in normal ovaries, 30%, 18.5% and 22.5% in benign epithelial tumours and 51%, 32% and 43% in malignant epithelial neoplasms.
The ovaries are under the trophic control of the pituitary gonadotrophins, follicle-stimulating hormone (FSH) and luteinising hormone (LH): a third pituitary hormone, prolactin, almost certainly has a role, though currently an ill defined one, in the control of ovarian function. The part played by these hormones, particularly the gonadotrophins, in ovarian tumour genesis is currently a matter of considerable interest, largely because of the possibility that hypergonadotrophism may be an aetiological factor in ovarian neoplasia (Beamer, 1981) .
Biochemical studies have demonstrated specific receptors for gonadotrophins and prolactin in the normal human ovary (Poindexter et al., 1979; McNeilly et al., 1980; Kammerman, 1980 Kammerman, , 1981 Rao et al., 1981) and in ovarian neoplasms (Davy et al., 1977; Kammerman et al., 1980 Kammerman et al., , 1981 Rajaniemi et al., 1981a) whilst immunoperoxidase techniques have been used to demonstrate gonadotrophin-binding sites in rat gonads (Petrusz & Uhlarik, 1973; Petrusz, 1974; Childs et al., 1978; Rajaniemi et al., 1981b) and prolactin-binding sites in human prostate gland (Witorsch, 1978) and in normal and neoplastic human breast tissue (Paterson et al., 1982; Purnell et al., 1982; Dhadley & Walker, 1983 ).
There have not, to the best of our knowledge, 
Materials and methods

Material
Tissue from 99 normal ovaries and from 141 ovarian neoplasms was studied (Table I) (1:100) for 30min: (iv) SAR (1:100) for 15min: (v) PAP (1:100) for 15 min. Unless noted otherwise all incubations were conducted in a moist chamber at room temperature. The sections were washed with TBS (pH 7.6) after exposure to the primary antisera, SAR and PAP.
The bound hormones were visualised by incubating the slides for 5min with a filtered freshly prepared solution of 50mg DAB in 100ml of TBS (pH 7.6) to which was added 0.02 ml of 30 vol hydrogen peroxide per 100 ml of substrate solution. The slides were then counterstained with haematoxylin, dehydrated to xylene and coverslipped with permount.
Specificity controls
Tissue controls Normal pituitary glands were used as positive controls for FSH, LH and PRL staining whilst sections from lung, myocardium and skeletal muscle were used as negative tissue controls.
Method controls In every staining run one component of the sequential staining reaction was omitted from at least one section. Usually the primary antiserum was replaced by normal rabbit serum but sometimes SAR or PAP was replaced by diluent buffer or DAB by TBS.
Absorption controls These were prepared by mixing a purified hormone preparation with the antiserum to this hormone for 24 h at 4°C prior to the inclusion of the antiserum in the IP procedure.
Quantitation of results
The degree of binding was scored on the basis of the proportion of positively staining cases from + to + + +, an admittedly arbitrary and subjective grading system but nevertheless one which, in practice, gave reproducible results.
Statistical analysis
All the results obtained were subjected to a chisquare test, a probability level of P<0.05, being taken to represent statistical significance.
Results
A positive reaction for hormone binding was seen as a brown granular precipitate after addition of DAB. All the sections of presumably positive pituitary tissue controls for LH, FSH and PRL gave the expected positive result (Figure la Tables II-V. In the normal ovaries FSH binding was seen in the granulosa cells of the pre-antral and antral the general pattern of LH binding but a notably strong reaction was observed in the luteinised cells of corpora lutea (Figure 3) .
Of the 111 epithelial ovarian tumours studied, 46 (41.4%) stained positively for FSH binding, 29 (26%) for LH binding and 38 (34%) for PRL binding. As compared with normal ovarian tissue or with benign epithelial tumours there was a statistically significant excess of FSH binding in malignant epithelial tumours whilst the incidence of PRL binding was significantly greater in malignant epithelial ovarian tumours than in benign epithelial neoplasms of the ovary. There was no significant correlation between the presence of hormone binding sites and the menopausal status of the patient, the histological type of epithelial ovarian tumour, the degree of malignancy of ovarian epithelial tumours or with the presence or absence of metastatic disease.
Hormone binding sites were not demonstrated in mature ovarian teratomas or in metastatic tumours of the ovary but in sex cord stromal tumours, FSH binding was demonstrable in 37% of cases, LH binding in 42% and PRL binding in 31.5%.
Within ovarian neoplasms DAB granules were seen principally in the cytoplasm of the neoplastic epithelial cells (Figures 4 and 5 ) but in some cases staining was restricted to focal areas of the tumour cell membrane whilst in others staining was predominantly nuclear. A striking feature of the pattern with ovarian neoplasms was the marked heterogeneity of the tumour cells for binding sites to all the studied hormones, strongly staining cells being admixed with cells which gave totally negative staining reactions (Figure 6 ). 
Discussion
In this study FSH, LH and PRL binding sites have been demonstrated by immunohistochemical techniques in a considerable proportion of normal human ovaries and in many ovarian epithelial tumours. Our finding that formalin-fixed, paraffin embedded tissue sections can be used to detect both in vivo and in vitro binding sites is in accord with the results of other immunohistochemical studies of gonadotrophin binding sites in rat testes (Childs et al., 1978; Rajaniemi et al., 1981b) and rat ovaries (Petrusz & Uhlahrik, 1973; Petrusz, 1974; Petrusz & Sar, 1978) and with studies of PRL binding sites in rat ovaries (Nolin, 1978 (Nolin, , 1980 Dunaif et al., 1977 Dunaif et al., , 1982 in human, dog and rat prostatic tissue (Eletreby & Mahrous, 1979; Witorsch, 1978 Witorsch, , 1979a Witorsch, , 1979b Purnell et al., 1982) , dog breast tissue ( Eletreby & Mahrous, 1979) and mouse adrenal gland (McDonough & Ewig, 1982) . Dhadley and Walker (1983) were, however, unable to detect PRL binding in paraffin-embedded sections of human breast tissue and advocated the sole usage of frozen sections: it appears therefore that the stability of binding sites for PRL varies from organ to organ. The validity of immunoperoxidase techniques for the demonstration of hormone receptor sites has been subjected to stringent criticism (Zehr et al., 1981; McCarty et al., 1981; Underwood, 1983) but we have elsewhere countered these arguments (AlTimimi et al., 1985) Kammerman (1980 ), Kammerman et al. (1981 and Rajaniemi et al. (1981) . Our results in respect to PRL binding in normal human ovarian tissue are also in accord with previous biochemical studies (Poindexter et al., 1979; McNeilly et al., 1980) : there have been no previous reports of the frequency of PRL binding in ovarian enithelial tumours but our results for neoDIasms of this type correspond very closely to reports of the incidence of biochemically assayable PRL receptors in human breast carcinomas (Di Carlo et al., 1980; Turcot-Lemay & Kelly, 1982) .
In this study those ovarian epithelial neoplasms showing a positive reaction for FSH, LH or PRL binding showed a striking degree of heterogeneity with strongly staining cells admixed with totally negative cells. This was not unexpected but in addition, however, ovarian adrenocarcinomas were heterogenous in respect to the cellular localisation of bound gonadotrophins and prolactin. A similar heterogeneity of cellular staining pattern has previously been noted in rat prostatic carcinomas (Witorsch, 1979a,b) , in human prostatic carcinoma (Purnell et al., 1982) and in human breast carcinomas (Paterson et al., 1982; Purnell et al., 1982; Dhadley & Walker, 1983 (Rao et al., 1981; Rajandran & Menon, 1983) . Immunoperoxidase studies have also shown that intracellular prolactin is present in rat ovaries (Dunaif et al., 1977 (Dunaif et al., , 1982 Nolin, 1978 Nolin, , 1980 and in human breast and prostatic tissue (Purnell et al., 1982) whilst intracellular gonadotrophins have been demonstrated in rat ovary (Petrusz & Uhlarik, 1973; Petrusz, 1974; Petrusz & Sar, 1978) and human prostate (Sibley, 1981) .
Our findings in respect to the clinical or prognostic value of the demonstration of gonadotrophin and prolactin binding sites were disappointing. It would have been expected that well differentiated epithelial tumours were more likely to have demonstrable hormone binding sites than would poorly differentiated neoplasms but this proved not to be the case. It is worth noting, however, that the strength of the reaction obtained did vary considerably with the degree of tumour differentiation. Thus, the staining reaction for FSH binding was strong (+ + +) in 54% of well differentiated tumours showing binding for this hormone but attained this degree of staining intensity in only 22% of positively reacting neoplasms which were poorly differentiated. The equivalent figures for LH binding were 37.5 and 0% whilst those for prolactin binding were 36 and 0%. These figures suggest that whilst the number of cells with hormone binding sites does not alter with decreasing differentiation of an ovarian tumour the number of binding sites in each individual cell does, there being a progressive decrease in staining intensity with decreasing degrees of cellular differentiation.
The incidence of FSH binding was significantly higher in malignant epithelial neoplasms than in either normal ovaries or benign epithelial neoplasms. This observation can, of course, be interpreted in several ways but would certainly tend to support the view that FSH plays a role in ovarian tumourigenesis. It has traditionally been thought, however, that if FSH does indeed play a role in this respect it does so by increasing the number of inclusion cysts derived from the ovarian surface epithelium rather than by promoting malignant change in such cysts. The observation that an increased incidence of FSH-binding was noted in malignant but not in benign epithelial neoplasms of the ovary would tend to argue against this concept.
